QIAN Stock Chart & Stats
$912.70
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$811.73 - $912.70
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
$149.06B
Enterprise Value$9.37K
Total Cash (Recent Filing)$646.29M
Total Debt (Recent Filing)$1.65B
Price to Earnings (P/E)21.9
Beta>-0.01
Next Earnings
Aug 05, 2026EPS Estimate
10.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.89
Shares Outstanding206,074,750
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.61
Price to Sales (P/S)4.71
P/FCF Ratio21.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$731.03Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Qiagen News
QIAN FAQ
What was Qiagen’s price range in the past 12 months?
Qiagen lowest stock price was $811.73 and its highest was $912.70 in the past 12 months.
What is Qiagen’s market cap?
Qiagen’s market cap is $149.06B.
When is Qiagen’s upcoming earnings report date?
Qiagen’s upcoming earnings report date is Aug 05, 2026 which is in 10 days.
How were Qiagen’s earnings last quarter?
Qiagen released its earnings results on May 06, 2026. The company reported $9.455 earnings per share for the quarter, missing the consensus estimate of $9.49 by -$0.035.
Is Qiagen overvalued?
According to Wall Street analysts Qiagen’s price is currently Undervalued.
Does Qiagen pay dividends?
Qiagen does not currently pay dividends.
What is Qiagen’s EPS estimate?
Qiagen’s EPS estimate is 10.49.
How many shares outstanding does Qiagen have?
Qiagen has 206,074,750 shares outstanding.
What happened to Qiagen’s price movement after its last earnings report?
Qiagen reported an EPS of $9.455 in its last earnings report, missing expectations of $9.49. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Qiagen?
Currently, no hedge funds are holding shares in MX:QIAN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Qiagen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$731.03 (― Downside)
$731.03 (― Downside)
Blogger Sentiment
Bullish
MX:QIAN Sentiment 70%
Sector Average 65%
Sector Average 65%
Insider Transactions
Bought Shares
Worth $52.7M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.15%
12-Months-Change
Fundamentals
Return on Equity
6.82%
Trailing 12-Months
Asset Growth
4.27%
Trailing 12-Months
Company Description
Qiagen
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
QIAN Stock 12 Month Forecast
Average Price Target
$731.03







